More Sunshine Lake Pharma Co., Ltd. Class H news
Sunshine Lake Pharma Co., Ltd. Class HHKEX: 6887

Next Day Disclosure Return

Sep 28, 2026 at 10:59 AM UTC · HKEXnews

HKEX: 6887

View Attachment

Original release on HKEXnews

Earlier from Sunshine Lake Pharma Co., Ltd. Class H

  • Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)May 4
  • Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 BillionAug 5, 2025
All Sunshine Lake Pharma Co., Ltd. Class H news releases↗